# Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

> **NCT01268280** · PHASE2 · TERMINATED · sponsor: **Cytokinetics** · enrollment: 32 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** Placebo
- **DRUG:** 250 mg CK-2017357
- **DRUG:** 500 mg CK-2017357

## Key facts

- **NCT ID:** NCT01268280
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Closed after complete treatment of 32 patients after 21 months' recruitment.
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268280, "Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01268280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*